rabeprazole has been researched along with Intestinal Diseases in 6 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, K | 1 |
| Cheng, X | 1 |
| Jin, R | 1 |
| Han, T | 1 |
| Li, J | 1 |
| Nuki, Y | 2 |
| Umeno, J | 1 |
| Washio, E | 2 |
| Maehata, Y | 2 |
| Hirano, A | 1 |
| Miyazaki, M | 2 |
| Kobayashi, H | 2 |
| Kitazono, T | 2 |
| Matsumoto, T | 2 |
| Esaki, M | 3 |
| Srinivas, NR | 1 |
| Shi, S | 1 |
| Wang, H | 1 |
| Gao, H | 1 |
| Li, Z | 1 |
| Chen, FX | 1 |
| Zuo, XL | 1 |
| Li, YQ | 1 |
| Ishikawa, H | 1 |
2 trials available for rabeprazole and Intestinal Diseases
| Article | Year |
|---|---|
The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.
Topics: Adult; Capsule Endoscopy; Celecoxib; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Genotype | 2017 |
Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Celecoxib; Double-Blind Method; F | 2016 |
4 other studies available for rabeprazole and Intestinal Diseases
| Article | Year |
|---|---|
The influence of different proton pump inhibitors and potassium-competitive acid blockers on indomethacin-induced small intestinal injury.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; DNA, Ribo | 2022 |
Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury-authors' reply.
Topics: Celecoxib; Cytochrome P-450 CYP2C19; Humans; Intestinal Diseases; Intestine, Small; Rabeprazole | 2017 |
Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.
Topics: Aryl Hydrocarbon Hydroxylases; Celecoxib; Cytochrome P-450 CYP2C19; Humans; Intestinal Diseases; Int | 2017 |
Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biomarkers; Blotting, Western; | 2014 |